'Zymbilan® is probably the most effective documented symptom relief programme in the world, when it comes to addressing Psoriasis and other dry scaly skin conditions. As a part of my extensive clinical research, I have been able to demonstrate scientifically objective results that Zymbilan® has a highly significant favourable effect on skin quality and expression compared to placebo in subjects with mild to moderate psoriasis.'
DR ERLING THOM
PhD Pharmacology, Stanford University
With over 30 years of expertise in clinical trial management and clinical development, Dr. Thom is an independent researcher with extensive experience in the areas of cardiology, rheumatology, neurology, dermatology, nutrition, and several pharmacokinetic studies. Dr. Thom has been a director at Ciba-Geigy, and for many years has been a director at Parexel. With over 15,000 employees operating in more than 50 countries, Parexel is one of the world’s largest comprehensive drug development and contract research organisations.